- Home
- DX vs ANIP Comparison
DX vs ANIP Comparison
Compare DX & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DX
- ANIP
- Stock Information
- Founded
- DX 1987
- ANIP 2001
- Country
- DX United States
- ANIP United States
- Employees
- DX N/A
- ANIP N/A
- Industry
- DX Real Estate Investment Trusts
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- DX Real Estate
- ANIP Health Care
- Exchange
- DX Nasdaq
- ANIP Nasdaq
- Market Cap
- DX 1.3B
- ANIP 1.4B
- IPO Year
- DX N/A
- ANIP N/A
- Fundamental
- Price
- DX $12.16
- ANIP $65.40
- Analyst Decision
- DX Buy
- ANIP Strong Buy
- Analyst Count
- DX 4
- ANIP 8
- Target Price
- DX $12.50
- ANIP $80.13
- AVG Volume (30 Days)
- DX 3.8M
- ANIP 283.5K
- Earning Date
- DX 07-21-2025
- ANIP 08-05-2025
- Dividend Yield
- DX 16.71%
- ANIP N/A
- EPS Growth
- DX N/A
- ANIP N/A
- EPS
- DX 0.79
- ANIP N/A
- Revenue
- DX $108,019,000.00
- ANIP $674,068,000.00
- Revenue This Year
- DX N/A
- ANIP $30.52
- Revenue Next Year
- DX $23.37
- ANIP $7.40
- P/E Ratio
- DX $15.41
- ANIP N/A
- Revenue Growth
- DX N/A
- ANIP 30.27
- 52 Week Low
- DX $10.79
- ANIP $52.50
- 52 Week High
- DX $14.52
- ANIP $77.00
- Technical
- Relative Strength Index (RSI)
- DX 47.19
- ANIP 58.76
- Support Level
- DX $12.00
- ANIP $63.80
- Resistance Level
- DX $12.14
- ANIP $67.42
- Average True Range (ATR)
- DX 0.17
- ANIP 1.75
- MACD
- DX -0.00
- ANIP 0.60
- Stochastic Oscillator
- DX 48.57
- ANIP 78.62
About DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including, residential MBS and commercial MBS.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.